Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMD011 monotherapy in advanced hepatocellular carcinoma (Phase I/IIa)
ChiCTR2300078740Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CMD011 in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective response rate. Started Dec 2023; status: recruiting.
02
Drugs
CMD011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300078740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078740.